Supplements
GAA and creatine in 25 older adults: a pilot found a borderline grip-strength difference
By Monica O'Reilly
Published · Updated

Twenty-five adults aged 65 and over were randomized in an exploratory pilot comparing guanidinoacetic acid, or GAA, with creatine monohydrate. The findings below come from the published abstract. Twenty-one completed it. The grip-strength comparison produced a borderline statistical signal with a wide confidence interval, giving researchers a reason for a larger trial.
The paper was published on August 31, 2026, in the Journal of Nutritional Science and Vitaminology. Coverage from November 12 to 14 brought it renewed attention this week.
What the pilot tested
The randomized, double-blind trial lasted eight weeks. Participants received GAA at 2.0 grams a day or an equimolar dose of creatine monohydrate, with no structured exercise. Eleven people completed the GAA arm and ten completed the creatine arm. These are trial doses, included to describe the comparison.
Grip strength: separate the two statistical questions
Handgrip strength rose significantly within the GAA group, with p=0.01. The within-group change with creatine was not significant. Those separate within-group results alone cannot establish a difference between treatments.
The time-by-treatment interaction was p=0.04. The reported between-group Hedges g was 0.91, with a 95% confidence interval from 0.00 to 1.81. That borderline result and wide interval come from a small pilot with 21 completers.
Body composition and blood markers
Within the GAA group, fat-free mass, body cell mass, muscle mass and total body water increased. The abstract reports no comparable increases with creatine. These were multifrequency bioelectrical impedance estimates. The trial used neither DXA nor MRI, and total body water increased alongside the other estimates.
Both supplements lowered circulating myostatin, with a larger reduction reported for GAA. Creatine produced a modest albumin reduction within the reference range. IGF-1 was below assay detection in most participants, so the researchers could not assess it.
What the safety reporting covers
No adverse events were reported in this trial. Compliance exceeded 97%. The News Tribune coverage says the study measured neither urinary nor blood creatinine. The abstract does not mention creatinine.
So what
For older readers comparing supplements, this pilot offers an early grip-strength signal to watch. Its small sample, short duration and wide interval limit confidence in the comparison. The results provide no basis here for a personal GAA dosing recommendation.
This pilot included no structured exercise. For background on creatine, see OP's creatine evidence guide.
Why confirmation matters
The authors call the findings preliminary and hypothesis-generating, and ask for adequately powered trials targeting sarcopenia. WellnessSorted’s coverage concludes that GAA superiority over creatine has yet to be shown. The between-group statistics and the small number of completers deserve more weight than the separate within-group significance labels.
This report is based on the published abstract, and secondary coverage is identified separately. We have not reviewed the full paper. For personal medical or supplement decisions, consult a qualified health professional.
Sources (3)
- Todorovic, Nedeljkovic, Korovljev, Stajer, Premusz, Acs and Ostojic, Journal of Nutritional Science and Vitaminology 72(4), August 31, 2026: exploratory GAA versus creatine pilot (primary abstract)
- News Tribune, November 12, 2026: secondary coverage of the GAA versus creatine pilot
- WellnessSorted, November 13, 2026: secondary coverage of GAA versus creatine
This is news reporting and not medical advice.